53 related articles for article (PubMed ID: 27889418)
1. A Statewide Intervention Improves Appropriate Imaging in Localized Prostate Cancer.
Hurley P; Dhir A; Gao Y; Drabik B; Lim K; Curry J; Womble PR; Linsell SM; Brachulis A; Sexton DW; Ghani KR; Denton BT; Miller DC; Montie JE;
J Urol; 2017 May; 197(5):1222-1228. PubMed ID: 27889418
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging.
Makarov DV; Loeb S; Ulmert D; Drevin L; Lambe M; Stattin P
J Natl Cancer Inst; 2013 Sep; 105(17):1306-13. PubMed ID: 23853055
[TBL] [Abstract][Full Text] [Related]
3. Determinants of the overuse of imaging in low-risk prostate cancer: A systematic review.
Oakes AH; Sharma R; Jackson M; Segal JB
Urol Oncol; 2017 Nov; 35(11):647-658. PubMed ID: 28943200
[TBL] [Abstract][Full Text] [Related]
4. Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?
Eifer M; Alipour R; Hofman MS; Kumar ASR
J Nucl Med; 2023 Nov; 64(11):1748-1749. PubMed ID: 37591549
[No Abstract] [Full Text] [Related]
5. Patient-Friendly Summary of the ACR Appropriateness Criteria®: Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2023 Update.
Newman R; Heller SL
J Am Coll Radiol; 2024 Mar; 21(3):e5. PubMed ID: 37871635
[No Abstract] [Full Text] [Related]
6. Revamping Prostate MRI Protocols: From Simple Modifications to Quality Improvement.
Almansour H; Chernyak V
Radiology; 2023 Oct; 309(1):e232398. PubMed ID: 37815444
[No Abstract] [Full Text] [Related]
7. True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC).
Böker A; Kuczyk MA; Kramer MW; Merseburger AS; Krüger K; Imkamp F; von Klot CA
Adv Ther; 2017 Jan; 34(1):171-179. PubMed ID: 27889882
[TBL] [Abstract][Full Text] [Related]
8. Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials.
Menichetti J; Villa S; Magnani T; Avuzzi B; Bosetti D; Marenghi C; Morlino S; Rancati T; Van Poppel H; Salvioni R; Valdagni R; Bellardita L
Crit Rev Oncol Hematol; 2016 Dec; 108():13-22. PubMed ID: 27931831
[TBL] [Abstract][Full Text] [Related]
9. PSA-Stratified Performance of
Dietlein F; Kobe C; Neubauer S; Schmidt M; Stockter S; Fischer T; Schomäcker K; Heidenreich A; Zlatopolskiy BD; Neumaier B; Drzezga A; Dietlein M
J Nucl Med; 2017 Jun; 58(6):947-952. PubMed ID: 27908968
[TBL] [Abstract][Full Text] [Related]
10. SEOM Clinical Guideline for bone metastases from solid tumours (2016).
Grávalos C; Rodríguez C; Sabino A; Seguí MÁ; Virizuela JA; Carmona A; Cassinello J; Isla D; Jara C; Martín M
Clin Transl Oncol; 2016 Dec; 18(12):1243-1253. PubMed ID: 27896639
[TBL] [Abstract][Full Text] [Related]
11. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
[TBL] [Abstract][Full Text] [Related]
12. Low Prostate-Cancer Mortality No Matter the Treatment.
Slomski A
JAMA; 2016 Nov; 316(20):2078. PubMed ID: 27893127
[No Abstract] [Full Text] [Related]
13. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.
McKay RR; Werner L; Fiorillo M; Roberts J; Heath EI; Bubley GJ; Montgomery RB; Taplin ME
Clin Genitourin Cancer; 2017 Aug; 15(4):463-471. PubMed ID: 27890446
[TBL] [Abstract][Full Text] [Related]
14. The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
Narita T; Koie T; Ookubo T; Mitsuzuka K; Narita S; Yamamoto H; Inoue T; Hatakeyama S; Kawamura S; Tochigi T; Habuchi T; Arai Y; Ohyama C
Med Oncol; 2017 Jan; 34(1):1. PubMed ID: 27889880
[TBL] [Abstract][Full Text] [Related]
15. What are the features of high-performing quality improvement collaboratives? A qualitative case study of a state-wide collaboratives programme.
McGowan JG; Martin GP; Krapohl GL; Campbell DA; Englesbe MJ; Dimick JB; Dixon-Woods M
BMJ Open; 2023 Dec; 13(12):e076648. PubMed ID: 38097243
[TBL] [Abstract][Full Text] [Related]
16. Understanding the multilevel determinants of clinicians' imaging decision-making: setting the stage for de-implementation of low-value imaging.
Hwang S; Birken SA; Nielsen ME; Elston-Lafata J; Wheeler SB; Spees LP
BMC Health Serv Res; 2022 Oct; 22(1):1232. PubMed ID: 36199082
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of interventions that improve provider compliance to imaging guidelines for prostate cancer.
Pettit SM; Mikhail D; Feuerstein M
Can Urol Assoc J; 2022 Sep; 16(9):E490-E495. PubMed ID: 35426782
[TBL] [Abstract][Full Text] [Related]
18. Interventions to reduce low-value imaging - a systematic review of interventions and outcomes.
Kjelle E; Andersen ER; Soril LJJ; van Bodegom-Vos L; Hofmann BM
BMC Health Serv Res; 2021 Sep; 21(1):983. PubMed ID: 34537051
[TBL] [Abstract][Full Text] [Related]
19. The past, present, and future of urological quality improvement collaboratives.
Reese AC; Ginzburg S
Transl Androl Urol; 2021 May; 10(5):2280-2288. PubMed ID: 34159110
[TBL] [Abstract][Full Text] [Related]
20. Prospective monitoring of imaging guideline adherence by physicians in a surgical collaborative: comparison of statistical process control methods for detecting outlying performance.
Inadomi M; Singh K; Qi J; Dunn R; Linsell S; Denton B; Hurley P; Kleer E; Montie J; Ghani KR;
BMC Med Inform Decis Mak; 2020 May; 20(1):89. PubMed ID: 32404086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
